WASHINGTON — The Department of Health and Human Services is moving forward with a policy that could require drug companies to put the price of their medicine in advertisements.
The White House Office of Management and Budget received a draft regulation from HHS this week titled “Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency.” An HHS spokesperson declined to comment on what the regulation would do, but lobbyists told STAT that it relates to the policy of requiring drug price information in ads.
The submission of the draft rule was first reported by Politico. Some experts have been skeptical of arguments that the disclosure of prices in drug ads could benefit patients. The amount of money patients pay for a medicine depends on a variety of circumstances, including their insurance plan and how much money they have spent on health care so far that year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
